February 2017 - Exhibiting at the 7th World ADC Summit in Berlin

YProtech will be exhibiting at the 7th World ADC Summit Berlin on 20-22 February. Please come and join us.

January 2017 - Launch of new toxin product NBoc-O-benzyl-seco-CBI (CAS 128300-11-8)

The seco-CBI core is an advanced intermediate for the synthesis of CBI related Duocarmycin analogues targeting novel warheads and payloads for ADC. We can supply gram quantities of this material.

January 2017 - YProtech opens High Potency Facility

The installation of a high potency facility marks the second phase of our expansion strategy. The expansion enables YProtech to offer dedicated chemistry services for the non-GMP synthesis and manufacture of cytotoxic compounds on multigram scale to support pre-clinical development in the pharma and biotech sectors. The facility includes a clean room with isolator for the handling and isolation of cytotoxins, dedicated high containment chemistry laboratory with multiple fume cupboards for the synthesis of cytotoxins, automated purification capability and access to LCMS and NMR for compound analysis. Find out more here.

Nov 2016 - YProtech exhibiting at Genesis 2016

We will be exhibiting at Genesis 2016 on 1st December, London. The theme of Genesis 2016 is The Science, Technology and Business of 21st Century Biomedical Innovation. This reflects that the conference agenda will showcase success in the application of biomedical research, innovative technologies and leading edge business strategies in order to deliver effective benefit to patients globally. YProtech will be part of the Life Sciences in the Northern Powerhouse stand. Find out more here.

Nov 2016 - EPSRC Grant for Organic Synthesis with the University of York

Professor Peter O’Brien and Dr Peter Karadakov, together with academic partner Professor Jacques Maddaluno (Rouen) and industrial partners AstraZeneca and YProtech, have been awarded a new Engineering and Physical Sciences Research Council (EPSRC) research grant. The grant is entitled “C–H Functionalisation of Cyclic Ethers: New Routes to 3-D Fragments, Scaffolds and Pharmaceuticals” and will support a post-doctoral researcher for 3.5 years. Additional information can be found here.